Asthma: Study 1
The purpose of this study is for doctors to learn more about the safety and effectiveness of two different doses of lebrikizumab that are injected just beneath the skin compared to placebo injections. Placebo is a liquid that looks the same as lebrikizumab, but contains no active ingredients. Uncontrolled asthma is defined, for the purposes of this study, as symptoms such as wheezing, chest tightness, cough, and shortness of breath despite taking conventional asthma medications.
- Males and females age 18-75 who meet spirometry criteria
- Must have been on inhaled corticosteroid therapy for at least 6 months prior to Visit 1
- Uncontrolled asthma demonstrated at Visit 1 and/or Visit 2, and Visit 3
- Other significant lung disease
- Pregnancy or breast feeding females
- Hepatitis, HIV
- Current malignancy or current evaluation for a potential malignancy
Your participation in this study could last approximately 2.5 years including screening, study-drug dosings and follow up. Visits will require spirometry. Other study procedures include physical examination, laboratory testing, ECG and completion of questionnaires. Patients will maintain a diary for study purposes between visits. All related medical care and study medications may be provided at no charge. Qualified participants will receive compensation for time and travel.